产品中心

产品货号

产品名称

规格

销售价

会员价

货期

产地

订购

C542

Recombinant Human SPINK1/Pancreatic secretory trypsin inhibitor/PST1

10ug

840

756

现货

国产

C542

Recombinant Human SPINK1/Pancreatic secretory trypsin inhibitor/PST1

50ug

2520

2268

现货

国产

C542

Recombinant Human SPINK1/Pancreatic secretory trypsin inhibitor/PST1

500ug

12320

11088

现货

国产

C542

Recombinant Human SPINK1/Pancreatic secretory trypsin inhibitor/PST1

1mg

17600

15840

现货

国产

  • 产品简介
  • 使用说明
  • 相关产品
  • 参考文献
  • 购买咨询
  • Catalog# C542
    Source HEK293
    Description Recombinant Human Serine Protease Inhibitor Kazal-Type 1/SPINK1 produced by transfected human cells is a secreted protein with sequence (Asp24-Cys79) of Human SPINK1 fused with a polyhistidine tag at the C-terminus.
    Names Pancreatic Secretory Trypsin Inhibitor, Serine Protease Inhibitor Kazal-Type 1, Tumor-Associated Trypsin Inhibitor, TATI, SPINK1, PSTI
    Accession # P00995
    Formulation Supplied as a 0.2 μm filtered solution of 20mM MES, 150mM NaCl, 2mM CaCl2, 1mM DTT, 0.05% Brij35, 10% Glycerol, pH 6.0
    Shipping The product is shipped on dry ice/ice packs.
    Storage Store at < -20°C, stable for 6 months after receipt.
    Please minimize freeze-thaw cycles.
    Purity Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE.
    Endotoxin Less than 0.1 ng/μg (1 IEU/μg).
    Amino Acid Sequence
    DSLGREAKCYNELNGCTKIYDPVCGTDGNTYPNECVLCFENRKRQTSILIQKSGPCVDHHHHHH
    Background Serine Protease Inhibitor Kazal-Type 1 (SPINK1) is a trypsin inhibitor that prevent the trypsin-catalyzed premature activation of zymogens within the pancreas. Defects in SPINK1 are a cause of pancreatitis (PCTT). A disease characterized by the presence of calculi in pancreatic ducts. It causes severe abdominal pain attacks. Defects in SPINK1 are the cause of susceptibility to tropical calcific pancreatitis (TCP). Recombinant SPINK1 protein (rSPINK1) stimulated cell proliferation in benign RWPE as well as cancerous prostate cells. The research result indicated that the potential of SPINK1 as an extracellular therapeutic target in prostate cancer. In contrast, knockdown of SPINK1 in 22RV1 cells inhibited cell proliferation, cell invasion, and tumor growth in xenograft assays.